Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Taylor Morrison Home
TMHC
Adobe
ADBE
KB Home
KBH
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 84.780
- -1.920-2.21%
Close Dec 30 16:00 ET
- 85.310
- +0.530+0.63%
Post 20:01 ET
4.11BMarket Cap-12.88P/E (TTM)
84.980High75.560Low3.53MVolume82.000Open86.700Pre Close284.47MTurnover9.75%Turnover RatioLossP/E (Static)48.46MShares105.00052wk High44.23P/B3.07BFloat Cap64.11052wk Low--Dividend TTM36.24MShs Float109.940Historical High--Div YieldTTM10.87%Amplitude1.940Historical Low80.505Avg Price1Lot Size
About Axsome Therapeutics Company
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Company Profile
SymbolAXSM
Company NameAxsome Therapeutics
Listing DateNov 19, 2015
Issue Price9.00
Founded2012
CEODr. Herriot Tabuteau, M.D.
MarketNASDAQ
Employees545
Fiscal Year Ends12-31
AddressOne World Trade Center,22nd floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10007
Phone1-212-332-3241
Websitehttp://www.axsome.com
Company Executives
- Name
- Position
- Salary
- Dr. Herriot Tabuteau, M.D.
- Chairman of the Board, President and Chief Executive Officer
- 9.90M
- Nick Pizzie
- Chief Financial Officer and Principal Accounting Officer
- 3.57M
- Mark Jacobson, M.A.
- Chief Operating Officer
- 4.04M
- Ari Maizel
- Executive Vice President, Head of Commercial
- --
- Lori Englebert
- Executive Vice President, Product Strategy
- --
- Dr. Mark Coleman, M.D.
- Independent Director
- 427.84K
- Mark E. Saad
- Independent Director
- 405.34K
- Dr. Susan Mahony, M.B.A.,PhD
- Independent Director
- 417.48K
- Dr. Roger A. Jeffs, PhD
- Lead Independent Director
- 400.34K
- Hunter Murdock
- General Counsel
- 3.06M
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.